Evidence map›Paper›PMID 31161271›Full record

ArticlePharmaceutical research2019

MOF Capacitates Cyclodextrin to Mega-Load Mode for High-Efficient Delivery of Valsartan.

Wei Zhang, Tao Guo, Caifen Wang, Yuanzhi He, Xi Zhang, Guangyu Li, Yizhi Chen, Jun Li, Yangjing Lin, Xu Xu and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Metal-organic frameworks for advanced drug delivery.Acta pharmaceutica Sinica. B · 2021
    Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Wei ZhangSchool of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai, 201418, China.
Tao GuoCenter for Drug Delivery Systems Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Caifen WangCenter for Drug Delivery Systems Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Yuanzhi HeCenter for Drug Delivery Systems Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Xi ZhangShanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 230032, China.
Guangyu LiShanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 230032, China.
Yizhi ChenHainan Hualon Pharmaceutical Co., Ltd, Haikou, 570311, China.
Jun LiHainan Hualon Pharmaceutical Co., Ltd, Haikou, 570311, China.
Yangjing LinHainan Hualon Pharmaceutical Co., Ltd, Haikou, 570311, China.
Xu XuSchool of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai, 201418, China.
Li WuCenter for Drug Delivery Systems Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. track_wuly@163.com.
Suxia ZhangSchool of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai, 201418, China. Zhangsx@sit.edu.cn.
Jiwen ZhangSchool of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai, 201418, China. jwzhang@simm.ac.cn.ORCID http://orcid.org/0000-0002-6497-6606
Chinese Academy of Sciences · CNShanghai Institute of Technology · CN

Funding

Key Program for International Science and Technology Cooperation Projects of China 2016YFE0125100National Science and Technology Major Projects for "Major New Drugs Innovation and Development" 2018ZX09201005-009
6 · The paper itself

Abstract

purposeTo investigate the mechanism of enhancing solubility and bioavailability of water-insoluble drug, valsartan (VAL), with being mega-loaded by cyclodextrin metal organic framework (CD-MOF).

methodsVAL was successfully mega-loaded into CD-MOF by magnetic agitation of VAL in ethanolic solution. Characterizations including powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), synchrotron radiation-based Fourier transform-infrared spectroscopy (SR-FTIR)

resultsAs a carrier with payload 150% higher than conventional CD complexation, CD-MOF included molecules of VAL as complexations in the chambers of (γ-CD)

conclusionsThe new understanding of drug nanoclusters in CD-MOF will help to design more efficient drug delivery systems using CD-MOF carrier with nanocavities.

Indexed as

AnimalsAntihypertensive AgentsBiological AvailabilityCyclodextrinsDogsDrug LiberationMetal-Organic FrameworksNanoparticlesSolubilityValsartanAntihypertensive AgentsCyclodextrinsMetal-Organic FrameworksValsartanBioavailabilitycyclodextrinmetal-organic frameworksolubilityvalsartan

Identifiers

PMID31161271
OpenAlexW2948466086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.